Nevertheless, the cytotoxic activity of some tumor-directed CD4+ T-cell subsets is now considered an important arm of the MHC class II restricted immune defense (174), particularly in patients with a defective HLA-I pathway. The gene discussed is CD4; the disease is neoplasm.